Bioxcel Therapeutics Announced Topline Exploratory Efficacy Data From SERENITY At-home Pivotal Phase 3 Safety Trial, Which Demonstrated Bxcl501 Had Continued Effects And Consistent Benefit With Repeat Dosing For Agitation Associated With Bipolar D...

-0.96%

Bioxcel Therapeutics

BTAI

2.07

-0.96%

BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p<.05)
Complete resolution of agitation was significantly higher with BXCL501 compared to placebo across agitation episode severity (p<.0001)
BXCL501 showed a similar reduction in agitation symptoms over both the duration of the trial and number of treated episodes, demonstrating continued effects and consistent benefit with repeat dosing of BXCL501
Based on the large body of evidence and positive FDA feedback, Company plans to submit a sNDA in Q1 2026 for expanded usage of IGALMI in the outpatient setting

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.